- Presentations
- 0
- Brands
- 0
- Manufacturers
- 0
- Available from stock
- 0
Sipavibart is a medicine. It is available for export supply from India to licensed hospitals, importers and physicians, with the documents the destination country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- ATC classification
- J06BD09 Sipavibart · Immunoglobulin therapy, subgroup J06BD
- US FDA first approval
- Not recorded
- EU status
- Authorised
- Orphan designation
- No
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Identifiers
- UNII 977D2P9YYWCAS 2768288-97-5Q131456536
All presentations
No presentations of Sipavibart are listed yet. Ask us to source it
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Questions and answers
Is Sipavibart available for export from India?
No presentation of Sipavibart is listed yet, but our sourcing team can check licensed channels. Send a request with the strength, quantity and destination country.
Is Sipavibart authorised in the European Union?
Yes. Sipavibart has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
Does Sipavibart need cold chain shipping?
No listed presentation of Sipavibart is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Sipavibart in?
Sipavibart is classified under ATC code J06BD09 (Sipavibart).
References
- Kavigale: European public assessment report (EPAR). European Medicines Agency. Retrieved 8 September 2026
Request Sipavibart for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.